Updated On: 01 September, 2022 04:04 PM IST | New Delhi | PTI
Cervical cancer in India ranks as the second most frequent cancer among women between 15 and 44 years of age

Representative Image
India`s first indigenously developed quadrivalent Human Papilloma Virus (HPV) vaccine for the prevention of cervical cancer will be launched in a few months and made available to the people in an affordable price range of Rs 200-400, Serum Institute of India CEO Adar Poonawalla said on Thursday.
Speaking at an event held to announce the scientific completion of the vaccine, Union Minister of Science and Technology Jitendra Singh said the vaccine will be affordable and the government will ensure that it is accessible to the common man.